Safety of Tirofiban Therapy in Korean Patients With Acute Coronary Syndrome
| Autor: | Joon Hoon Jeong, Kook Jin Chun, Yong Hyun Park, Yung Woo Shin, Taek Jong Hong, June Hong Kim |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Acute coronary syndrome medicine.medical_specialty medicine.medical_treatment Vascular access Coronary Disease Internal medicine medicine Humans In patient Angioplasty Balloon Coronary Aged Retrospective Studies Aged 80 and over Korea Medical treatment business.industry Percutaneous coronary intervention Syndrome General Medicine Tirofiban Middle Aged medicine.disease Anesthesia Conventional PCI Drug Evaluation Tyrosine Female Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Major bleeding medicine.drug |
| Zdroj: | Circulation Journal. 69:650-653 |
| ISSN: | 1347-4820 1346-9843 |
| DOI: | 10.1253/circj.69.650 |
| Popis: | Background Although it has been reported that the glycoprotein IIb/IIIa inhibitor, tirofiban, is beneficial in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI), there is little data concerning the risks and complications of tirofiban therapy in Korean patients. Methods and Results The present study reviewed 261 patients who underwent tirofiban administration for ACS between May 2002 and August 2003. The rates of bleeding, transfusion, and thrombocytopenia were analyzed and the rates of complications by age, gender, and PCI vs medical treatment werecompared. The rate of minor bleeding was 8.1% (21 patients), major bleeding was 2.3% (6 patients), transfusion was 4.6% (12 patients), and thrombocytopenia was 1.2% (3 patients). Minor bleeding showed a similar rate in both sexes (8% in males vs 8.1% in females) but was higher with older age (12.5% ≥65 vs 2.6% |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|